Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Metrics to compare | AADI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAADIPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −2.0x | −0.7x | |
PEG Ratio | −0.32 | 0.00 | 0.00 | |
Price/Book | 0.9x | 0.9x | 2.6x | |
Price / LTM Sales | 2.4x | 4.9x | 3.2x | |
Upside (Analyst Target) | −24.4% | 314.8% | 45.9% | |
Fair Value Upside | Unlock | 8.0% | 7.6% | Unlock |